Dyne Therapeutics, Inc. (DYN) saw its stock price plummet 5.03% during intraday trading on Friday, reflecting significant negative sentiment among investors.
The sharp decline followed news that investment firm Evercore ISI lowered its price target on Dyne Therapeutics to $33 from $34, while maintaining an Outperform rating on the shares. Analyst price target reductions often signal tempered expectations for a company's future performance, which can trigger immediate selling pressure as investors reassess their positions.